One of the Deepest Pools of Capital on Earth Is Quietly Splitting in Two

The Night Shift: Boston Edition

Boston-based institutions manage roughly $5.2 trillion in long-term assets and hold more than $40 trillion under custody and administration. Fidelity alone reported $7.0 trillion in managed assets as of Q1 2026, up 19% year over year, alongside $17.9 trillion under administration. State Street manages another $5.6 trillion, with $54.5 trillion under custody. Wellington Management, Putnam, MFS, Geode Capital, Eaton Vance's legacy, all headquartered here. By any measure of scale, this is one of the most concentrated pools of institutional capital anywhere in the world.

It's also, right now, quietly splitting into two very different businesses, often inside the same firm.

The Traditional Side Is Under Real, Structural Pressure

Active, fundamental equity management, the classic stock-picking discipline that built Fidelity's reputation through figures like Peter Lynch, is losing fee revenue at an estimated 2-3% of assets under management annually, as capital keeps migrating toward passive index products. That's not a cyclical dip. Average expense ratios on actively managed equity funds have fallen steadily, from 0.82% in 2014 to 0.60% in 2024, according to the Investment Company Institute, and Deloitte's 2025 Investment Management Outlook projects another 8-12% of fee compression in core equity products by the end of 2026. Active mutual funds saw $280 billion in national outflows in a single recent year, and Boston's historic concentration in exactly this kind of active equity strategy meant the city absorbed a disproportionate share of that pressure.

For a traditional fundamental portfolio manager or research analyst in this city, that's a genuine, ongoing structural squeeze, not a bad quarter.

The Other Side Is Expanding Fast

At the same time, and often at the very same firms, a different discipline is growing quickly enough to reshape the city's own commercial real estate. Systematic strategies, private credit, and AI-driven quantitative approaches have expanded so fast that Boston asset managers grew their combined Seaport and Back Bay office footprint by 12% between 2022 and 2024. Wellington Management and MFS, both historically built around traditional active management, have been actively expanding into private credit and systematic macro capabilities. Geode Capital Management, spun out of Fidelity in 2001 as a small quantitative unit, now independently manages $1.3 trillion.

Why This Split Matters More Than Either Half Alone

Here's the part that actually matters if you work in or near this industry: the split doesn't run between firms. It runs inside them. Wellington isn't simply "a traditional shop" or "a systematic shop", it's visibly both at once, expanding one side while the other faces real fee pressure. The same is true across much of Boston's asset management landscape. That means a single, simple read on "how's Boston finance doing right now" is close to meaningless. The honest answer depends entirely on which specific discipline, within which specific firm, you're actually asking about.

What This Means If You're Networking in Boston Finance Right Now

"Asset management in Boston" isn't one conversation. It's at least two. Someone in traditional active equity research and someone in systematic or private credit strategy, even at the same firm, are living through genuinely different moments right now, one under fee pressure, the other in active expansion. Treating them as the same conversation misses what's actually happening to each of them.

The people who can tell you which side of the split a specific team sits on are unusually valuable right now. With the split running inside firms rather than between them, a job posting or a firm's overall reputation tells you less than it used to. A real conversation with someone actually on that specific team tells you the rest.

If you're on the traditional side, this is exactly the moment relationships outside your immediate discipline pay off. Wellington and MFS didn't abandon active management to build private credit and systematic capabilities, they built new capabilities alongside it, often by bringing in expertise from elsewhere. The bridge between the two sides of this split is built by people, not by strategy memos.

Boston's pool of institutional capital isn't getting smaller. It's reorganizing itself, quietly, discipline by discipline, inside firms whose names haven't changed even as what they actually do keeps shifting underneath them.

NetworkNite's format puts you across the table from people working in specific roles at specific firms, the only reliable way to know which side of a split like this someone is actually standing on. See how it works →

Boston Doesn't Have a Brain Drain Problem. It Has a Faster Clock.

The Night Shift: Boston Edition

Ask around Boston long enough and you'll hear the same worry repeated as fact: the city trains the country's best young talent, at Northeastern, Suffolk, UMass Boston, Boston College, MIT, Tufts, and dozens of others, and then watches most of it leave for New York or San Francisco. It's a tidy story. According to the city's own planning agency, it's also not quite the right question to be asking.

The City's Own Research Pushed Back on the Premise

A Boston Planning & Development Agency study examining exactly this question concluded that neither "brain drain" nor "retention rate" is actually a good indicator of how well Boston's economy is doing at holding onto young talent. The researchers point out a basic flaw in how these numbers usually get calculated: most retention studies count a graduate as "lost" the moment they leave the region at any point after graduation, even years later, even after a full career already built in Boston. That's not a realistic way to describe how people actually move through a labor market over a lifetime.

What the researchers argue actually matters is something different: the size and share of the population made up of college-educated young workers at any given time, not whether any one individual graduate eventually leaves.

The Number That Actually Matters

On that measure, Boston isn't losing. Nearly 17% of the city's population falls into the 25-to-34 age cohort enrolled in college, according to the BPDA's analysis, ahead of Chicago, New York, and Philadelphia, and just slightly behind San Francisco and Washington, D.C. That's a real, current, comparative figure, not a reputation. Boston isn't simply a city that produces graduates who leave. It's a city that maintains one of the highest concentrations of young, college-educated people of any major U.S. metro, continuously, even accounting for the ones who do eventually move on.

Why the Reframing Actually Matters for How You Network Here

If the old "brain drain" framing were true in the simple way it's usually told, the practical advice would be straightforward: build your network fast, because everyone worth knowing is about to leave. The city's own data suggests something more useful and more specific than that.

Boston's 25-to-34 population isn't a fixed group slowly draining away. It's closer to a continuously refilling reservoir: some people leave, genuinely, for New York or the Bay Area, but the overall share of young, college-educated people in the city stays remarkably high year over year, refilled by new graduating classes and by people who moved here specifically for that density of peers. The city isn't shrinking in this dimension. It's turning over, at a pace that outstrips most comparable cities.

That's a meaningfully different thing to plan a network around than either "everyone's leaving" or "everyone stays." It means the room is genuinely younger and more in-flux than a typical major city's, not because Boston is failing to hold onto people, but because it's constantly both losing and replacing them faster than most places do.

What This Means If You're Networking in Boston Right Now

Don't treat every connection as a long-term bet, or dismiss it as a short-term one. Some people you meet here genuinely will be gone within a couple of years. Others are part of the steady, comparatively large base the city's own data shows sticking around relative to peer cities. There's no shortcut to knowing which is which except an actual conversation.

The constant turnover is a reason to meet more people, not fewer. In a city with this much churn in its 25-to-34 population, waiting for your existing circle to organically introduce you to someone new works less well than it might in a more static city, your circle itself is turning over too.

Boston's density of young professionals is a genuine structural advantage, not just a reputation. Ahead of Chicago, New York, and Philadelphia on this specific measure is a real, comparative fact worth knowing, especially if you moved here believing the brain-drain story and expecting a thinner room than you're actually walking into.

The city isn't failing to hold onto its graduates. It's running a faster clock than most, and the practical difference between those two stories is exactly how you should be showing up to meet people here.

NetworkNite's format is built for a room that's genuinely in motion, guaranteed conversations with everyone there tonight, not a bet that you'll catch up with them next year. See how it works →

Empty Labs, Full Square: The Contradiction at the Heart of Boston Biotech Right Now

More than 600 life sciences companies operate inside a single square mile of Cambridge. Kendall Square and its surrounding cluster employ roughly 118,000 people directly in biopharma roles, with another 182,000 supported indirectly, together accounting for close to 18% of the entire Massachusetts economy. By reputation, and by those numbers, it's the most concentrated biotech hub on Earth.

Two other things are also true right now, and they point in opposite directions.

The Downturn Is Real, and It's Hitting Real Companies

By the fourth quarter of 2025, life-science lab vacancy across the greater Boston metro area hit an all-time high of 28%, according to CBRE, with total available lab space reaching a record 17 million square feet. Include sublease space, companies trying to offload space they're no longer using, and overall availability climbs to nearly 30%.

This isn't abstract. Takeda, the largest biopharmaceutical employer in Massachusetts, filed notice this year that it will lay off 247 employees at its Kendall Square headquarters as part of a board-approved restructuring, with cuts beginning in July. Seres Therapeutics announced a 30% workforce reduction. Thermo Fisher Scientific cut nearly 300 employees across its Cambridge and Plainville offices. A funding environment that once flowed freely into Kendall Square startups has slowed considerably, and PhD graduates who once expected a straightforward path into the sector are increasingly running into hiring freezes instead.

By any conventional read, this is an industry in contraction.

And Yet the Actual Center of the Cluster Is Still Essentially Full

Here's where it stops being a simple story. That record 28% vacancy figure describes the broader Boston metro, not Kendall Square itself. Inside the actual square mile, Class A lab space has been effectively at zero vacancy for more than a year. Incubators like LabCentral and CIC, the first stop for many early-stage biotech companies, report 98% occupancy with waitlists exceeding twelve months. Takeda itself, even while cutting Kendall Square headcount, recently leased roughly 600,000 additional square feet nearby to consolidate its R&D operations. Vertex Pharmaceuticals anchors 1.4 million square feet across the harbor in the Seaport, and that district alone has absorbed 1.2 million square feet of new lab development since 2023.

So the honest picture isn't "Boston biotech is struggling" or "Boston biotech is booming." It's a two-tier market: older or less centrally located lab space is sitting empty at record rates, while the actual physical and reputational core, Kendall Square proper, remains as saturated and competitive as ever.

The Same Split Shows Up in Hiring, Not Just Real Estate

Layer hiring on top of real estate and the picture sharpens further. Even amid broad industry layoffs, recruiters report that specific, highly specialized disciplines, cell and gene therapy manufacturing, AI-enabled drug discovery, and CMC regulatory affairs among them, have candidate-to-role ratios so imbalanced that conventional hiring approaches have stopped working. The industry isn't uniformly cutting or uniformly hiring. It's doing both simultaneously, sorted by specialization, not by headline sentiment.

What This Means If You're Networking in Boston Biotech Right Now

"Boston biotech is down" and "Boston biotech is up" are both incomplete on their own. The honest version is that the industry is bifurcating, by real estate tier, by specialization, and increasingly by which specific 600 companies you're talking about inside that one square mile. A blanket read on the sector, in either direction, will be wrong about a meaningful share of the people actually working in it.

The people who know which tier you're in are more valuable than any industry-wide headline. With vacancy and hiring diverging this sharply by sub-sector and specific address, a real conversation with someone actually working in cell and gene therapy manufacturing right now tells you more than any regional vacancy report or layoff headline.

Broad "biotech is struggling" narratives may be quietly discouraging exactly the specialists who are in shortest supply. If a talented CMC regulatory affairs candidate reads the Takeda layoff headline and assumes the whole field is contracting, that's a real cost, both to them and to the companies who can't find enough people in exactly that discipline.

Kendall Square isn't simply thriving or simply struggling. It's sorting itself, in real time, into who has room and who doesn't, and the only reliable way to know which side of that sort you're standing on is to actually talk to the people working inside it.

NetworkNite's format puts you across the table from people working inside specific companies and disciplines, the kind of real, current read a vacancy report or layoff headline can't give you. See how it works →